Double-Negative (PF4-Negative/SRA-Negative) Heparin-Induced Thrombocytopenia

Published:October 14, 2022DOI:
      Heparin-induced thrombocytopenia (HIT) is a disorder characterized by antibody-mediated platelet activation and vascular thrombosis in patients exposed to heparin. Traditionally, the diagnosis is supported by platelet-factor 4 (PF4)/heparin enzyme-immunoassay (EIA) and confirmed with a functional assay, like the serotonin release assay (SRA). We describe a patient with a clinical course highly suspicious for HIT despite an initially weakly positive, then negative, PF4 antibody and repeatedly negative SRA. This should alert clinicians to the growing evidence of double-negative (PF4 negative/SRA negative) HIT as a clinical entity.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Warkentin TE
        • Nazy I
        • Sheppard JI
        • Smith JW
        • Kelton JG
        • Arnold DM
        Serotonin-release assay-negative heparin-induced thrombocytopenia.
        Am J Hematol. 2020; 95: 38-47
        • Padmanabhan A
        • Jones CG
        • Curtis BR
        • et al.
        A novel PF4-dependent platelet activation assay identifies patients likely to have heparin-induced thrombocytopenia/thrombosis.
        Chest. 2016; 150: 506-515
        • Singh B
        • Jones C
        • Garcia DA
        • et al.
        PF4/polyanion ELISA-negative antibodies to PF4 and non-PF4 targets can mediate platelet activation and cause heparin-induced thrombocytopenia (HIT).
        Res Pract Thromb Haemost. 2021; 5